As a single-pass transmembrane receptor, LRP6 interacts with the frizzled (FZD) family and activates the Wnt/β-catenin signaling pathway, which has been demonstrated in many cancers, including breast cancer, prostate cancer, hepatocellular carcinoma, and retinoblastoma 40,42. This evidence concerns the gene LRP6 and prostate cancer.